# CagriSema (Cagrilintide + Semaglutide)

> CagriSema is an investigational combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, co-formulated as a single once-weekly injection. Phase 3 trial data have reported average weight reductions numerically greater than semaglutide alone in some analyses, positioning it among the more effective agents studied for weight management to date. It has not yet received regulatory approval. As with other late-stage investigational agents, published data are still limited relative to long-approved therapies.

- URL: https://www.lifeconverted.com/peptides/cagrisema
- Also known as: Cagrilintide/Semaglutide combination
- Primary category: Weight Management
- Effectiveness rank: #3 in Weight Management
- Evidence level: Moderate evidence
- Route: Subcutaneous (Co-formulated combination product; dosing figures reflect the semaglutide-equivalent titration scale used in published trials, alongside a matched cagrilintide component.)
- Dose range: 0.25-2.4 mg
- Dose tiers: low 0.25 mg; moderate 1.7 mg; high 2.4 mg
- Half-life: Approximately 7 days for each component, consistent with once-weekly dosing
- Timing: Weekly · same day, any time
- Cycle: Continuous use with titration over several months in trial protocols on, Not established outside of trial settings off (Titration pace mirrors semaglutide-based protocols to limit gastrointestinal side effects.)
- Storage: Refrigerate at 2-8°C; protect from light; do not freeze.

## Mechanism of action

Cagrilintide activates amylin receptors, which are involved in satiety signaling and slowed gastric emptying, while semaglutide activates GLP-1 receptors with similar downstream appetite and gastric-emptying effects. The combination is intended to engage two complementary satiety pathways simultaneously, which trial sponsors have proposed may produce additive effects on food intake and body weight beyond either component alone.

## Reported benefits

- Associated with greater average weight loss than semaglutide monotherapy in some trial comparisons
- Combines two complementary satiety-signaling pathways
- Once-weekly injection schedule
- May improve glycemic markers

## Reported side effects

- Nausea, vomiting, and diarrhea, especially during titration
- Decreased appetite
- Injection-site reactions
- Potential gallbladder-related events
- Long-term safety data remain limited

## Common protocols

- Trial-based step-up titration over multiple months
- Once-weekly subcutaneous injection with site rotation

## Stacking notes

As a fixed combination, it is not intended to be stacked with additional GLP-1 or amylin agents; doing so is not supported by evidence.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer